Last checked at 15 May 2009 16:04
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
DIRECTORATE CHANGES
15 May 2009: Celsis International plc, the life sciences products and laboratory services company, today announces the appointment of Jeremy Barnes as Non-Executive Director, and the resignation of Peter Jensen and Nicholas Badman with immediate effect.
Jeremy Barnes is an experienced corporate financier and was founder and CEO of Orbis Capital, since its incorporation in 2001. Orbis Capital has recently changed its name into Excalibur Capital, the successful corporate finance boutique. He subsequently became CEO of Merchant Ventures in 2006. From 1998 to 2000, Jeremy was Managing Director of XL Financial Solutions in London where he led a specialist team that structured and arranged insurance risk transfer deals for the Bermuda re-insurer, XL Capital. From 1993 to 1999, Jeremy was Director of Corporate Finance at British Aerospace where he led the team that placed a $3.8 billion insurance risk transfer deal relating to BAe's portfolio of 550 regional aircraft. From 1982 to 1991, Jeremy spent nine years at Citicorp where he specialised in corporate finance.
Jack Rowell, Non-Executive Chairman of Celsis, commented:
"I am pleased to announce this appointment which will substantially strengthen our Board. Jeremy Barnes brings with him a wealth of corporate finance experience, which will provide very valuable knowledge for our business.
This appointment reflects the Company's strategic orientations. Peter Jensen and Nicholas Badman have resigned from the Board. Each has served the Board with dedication and integrity and we thank them for their contribution.
The Board will continue to review its composition to meet the needs of the business and its corporate governance obligations and looks forward to guiding the Company through the next phase in its development under the executive leadership of Jay LeCoque and his team."
There are no further details to be disclosed under the Continuing Obligations provisions of the Listing Rules (new rules LR9.6.13).
Further information can be found on its website at www.celsis.com
| Enquiries: |
|
|
|
|
| Celsis International plc | Tel:01223 598 428 |
| Jay LeCoque |
|
| Robyn LaLonde |
|
|
|
|
| Nomura Code Securities | Tel:020 7776 1200 |
| Chris Collins |
|
| Phil Walker |
|
|
|
|
| Financial Dynamics | Tel:020 7831 3113 |
| Jonathan Birt |
|
| Susan Quigley |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical and Development Services provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.